Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1373/clinchem.2016.255794 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials.
High Blood Press Cardiovasc Prev
October 2024
University of Toledo, Toledo, OH, USA.
Article Synopsis
- * This review evaluates the effectiveness and safety of antisense oligonucleotides (ASOs) for treating dyslipidemia and explores their potential in personalized medicine for at-risk patients.
- * Clinical trials suggest that ASOs like Mipomersen and Volanesorsen may be more effective than traditional statins, offering fewer side effects and serving as alternative treatments for patients with inherited lipid disorders.
Repurposing lipid-lowering drugs on asthma and lung function: evidence from a genetic association analysis.
J Transl Med
July 2024
Department of Pediatrics, Xiangya Hospital, Central South University, Hunan, 410008, China.
Objective: To explore the correlation between asthma risk and genetic variants affecting the expression or function of lipid-lowering drug targets.
Methods: We conducted Mendelian randomization (MR) analyses using variants in several genes associated with lipid-lowering medication targets: HMGCR (statin target), PCSK9 (alirocumab target), NPC1L1 (ezetimibe target), APOB (mipomersen target), ANGPTL3 (evinacumab target), PPARA (fenofibrate target), and APOC3 (volanesorsen target), as well as LDLR and LPL. Our objective was to investigate the relationship between lipid-lowering drugs and asthma through MR.
Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
BioDrugs
July 2024
Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, USA.
Article Synopsis
- - Antisense oligonucleotides (ASOs) are single-stranded nucleic acids that specifically target RNA and have been approved by the FDA for various diseases, utilizing three main mechanisms of action: mRNA degradation, exon skipping, and mRNA function inhibition.
- - ASOs are structurally modified for stability and resistance to degradation, and examples include drugs like inotersen for hereditary transthyretin amyloidosis and nusinersen for spinal muscular atrophy.
- - The design of ASOs is largely based on mRNA sequence knowledge, making the development process quicker compared to traditional protein-targeted drugs, which enhances their potential for therapeutic applications.
Therapeutic Potential of Lipoprotein(a) Inhibitors.
Drugs
June 2024
Victorian Heart Institute, Monash University, 631 Blackburn Road, Clayton, Melbourne, VIC, 3168, Australia.
Increasing evidence has implicated lipoprotein(a) [Lp(a)] in the causality of atherosclerosis and calcific aortic stenosis. This has stimulated immense interest in developing novel approaches to integrating Lp(a) into the setting of cardiovascular prevention. Current guidelines advocate universal measurement of Lp(a) levels, with the potential to influence cardiovascular risk assessment and triage of higher-risk patients to use of more intensive preventive therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!